This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kümpfel, T. Articles by Weber, F. Search for Related Content PubMed PubMed Citation Articles by Kümpfel, T. Articles by Weber, F. Social Bookmarking                         What's this?

Time of interferon-ß 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients

Institute of Clinical Neuroimmunology, Klinikum Großhadern, Ludwig-Maximilians-Universität, Munich, Germany, tania.kuempfel{at}med.uni-muenchen.de

M. Schwan

Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany

Th. Pollmächer

Centre of Mental Health, Klinikum Ingolstadt, Ingoldstadt, Germany

A. Yassouridis

Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany

M. Uhr

Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany

C. Trenkwalder

Department of Clinical Neurophysiology, University of Goettingen, Germany

F. Weber

Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany

During initiation of interferon-beta (IFN-ß) therapy, many multiple sclerosis (MS) patients experience systemic side effects which may depend on the time point of IFN-ß injection. We investigated the time course of plasma hormone-, cytokine- and cytokine-receptor concentrations after the first injection of IFN-ß either at 8.00 a.m. (group A) or at 6.00 p.m. (group B) and quantified clinical side effects within the first 9 h in 16 medication free patients with relapsing-remitting MS. This investigation was repeated after 6-month IFN-ß therapy.

Plasma ACTH and cortisol concentrations followed their physiological rhythms, with lower levels in the evening compared to the morning, but raised earlier and stronger in group B after IFN-ß administration. IFN-ß injection in the evening led to a prompter increase of plasma IL-6 concentrations and temperature during the first hours and correlated to more intense clinical side effects compared to group A. Plasma IL-10 concentrations increased more in group A compared to group B, but sTNF-RI and sTNF-RII concentrations raised 7 h after IFN-ß injection only in group B. Acute effects on plasma hormone and cytokine concentrations adapted after 6-month IFN-ß treatment, while diurnal variations were still present. Baseline sTNF-RII concentrations were elevated after 6-month IFN-ß therapy only in group A.

Our results show that time point of IFN-ß injection has differential effects on acute changes of plasma hormone and cytokine concentrations and is related to systemic side effects. This may have implications on the tolerability and effectiveness of IFN-ß therapy. Multiple Sclerosis 2007; 13: 1138—1145. http://msj.sagepub.com

Key Words: time point of injection • interferon-ß • cytokine • hormones • side effects • multiple sclerosis

Multiple Sclerosis, Vol. 13, No. 9, 1138-1145 (2007)
DOI: 10.1177/1352458507078685


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Mendozzi, F. Tronci, M. Garegnani, and L. Pugnetti Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic study Multiple Sclerosis, February 1, 2010; 16(2): 238 - 247. [Abstract] [PDF]